Sionna Therapeutics, Inc. $SION is Orbimed Advisors LLC’s 8th Largest Position

Orbimed Advisors LLC decreased its position in Sionna Therapeutics, Inc. (NASDAQ:SION) by 0.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,530,702 shares of the company’s stock after selling 30,953 shares during the quarter. Sionna Therapeutics accounts for about 2.6% of Orbimed Advisors LLC’s investment portfolio, making the stock its 8th largest holding. Orbimed Advisors LLC owned approximately 0.08% of Sionna Therapeutics worth $141,546,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the company. Viking Global Investors LP lifted its position in shares of Sionna Therapeutics by 8.2% during the second quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock worth $55,436,000 after purchasing an additional 242,427 shares in the last quarter. Jennison Associates LLC grew its holdings in Sionna Therapeutics by 30.1% during the 1st quarter. Jennison Associates LLC now owns 1,451,220 shares of the company’s stock valued at $58,179,000 after purchasing an additional 335,942 shares in the last quarter. Vanguard Group Inc. increased its stake in Sionna Therapeutics by 3.7% during the 4th quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock worth $48,749,000 after buying an additional 41,797 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Sionna Therapeutics by 30.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 831,373 shares of the company’s stock worth $34,203,000 after buying an additional 193,613 shares during the period. Finally, State Street Corp lifted its holdings in Sionna Therapeutics by 188.7% in the 4th quarter. State Street Corp now owns 693,395 shares of the company’s stock worth $28,526,000 after buying an additional 453,196 shares in the last quarter.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. JonesTrading upped their price objective on shares of Sionna Therapeutics from $52.00 to $63.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. Wedbush began coverage on Sionna Therapeutics in a research note on Tuesday, May 5th. They issued an “outperform” rating and a $53.00 price target on the stock. BTIG Research reissued a “buy” rating and issued a $58.00 price target on shares of Sionna Therapeutics in a report on Wednesday, May 13th. Wall Street Zen lowered Sionna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Friday, May 8th. Three investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $53.22.

Sionna Therapeutics Stock Performance

SION opened at $45.70 on Monday. The company has a market capitalization of $2.06 billion, a P/E ratio of -23.68 and a beta of 1.33. The company has a 50-day moving average of $41.04 and a 200-day moving average of $39.78. Sionna Therapeutics, Inc. has a 1-year low of $16.38 and a 1-year high of $51.56.

Sionna Therapeutics (NASDAQ:SION) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.08). As a group, sell-side analysts expect that Sionna Therapeutics, Inc. will post -2.57 earnings per share for the current fiscal year.

Insider Activity at Sionna Therapeutics

In other Sionna Therapeutics news, Director Orbimed Advisors Llc sold 85,918 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the sale, the director owned 2,469,959 shares in the company, valued at $110,802,360.74. This represents a 3.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 85,918 shares of the stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total value of $3,854,281.48. Following the transaction, the director directly owned 2,469,959 shares in the company, valued at approximately $110,802,360.74. This represents a 3.36% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 989,630 shares of company stock worth $44,987,483 in the last 90 days. 5.10% of the stock is currently owned by insiders.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.